Navigation Links
Boston Scientific Announces Results for First Quarter Ended March 31, 2011
Date:4/20/2011

n evaluation of the Company's current operating performance and for comparison to the Company's past operating performance.
  • Amortization expense - Amortization expense is a non-cash charge and does not impact the Company's liquidity or compliance with the covenants included in its debt agreements. Management removes the impact of amortization from the Company's operating performance to assist in assessing the Company's cash generated from operations. Management believes this is a critical metric for the Company in measuring the Company's ability to generate cash and pay down debt. Therefore, amortization expense is excluded from management's assessment of operating performance and is also excluded from the measures management uses to set employee compensation. Accordingly, management has excluded amortization expense for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance, particularly in terms of liquidity.

  • Regional and Divisional Revenue Growth Rates Excluding the Impact of Foreign Exchange

  • Foreign exchange on net sales - The impact of foreign exchange is highly variable and difficult to predict. Accordingly, management excludes the impact of foreign exchange for purposes of reviewing regional and divisional revenue growth rates to facilitate an evaluation of the Company's current operating performance and comparison to the Company's past operating performance.

  • Adjusted net income, adjusted net income per share and regional and divisional revenue growth rates that exclude the impact of foreign exchange are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP measures. Further, other companies may calculate these non-GAAP financial measures differently than Boston Scientific does, which may limit the
    '/>"/>

    SOURCE Boston Scientific Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
    2. Boston Scientific Begins International Clinical Trial Enrollment for INNOVA™ Self-Expanding Bare-Metal Stent System
    3. Boston Scientific ION™ Platinum Chromium Stent System Demonstrates Strong Performance in Analysis of PERSEUS and TAXUS ATLAS Clinical Trial Data
    4. Hologic, Hospira, Boston Scientific, Allergan to Participate in Leading Medical Device Manufacturing Symposium
    5. Boston Scientific Announces Its ACC 2011 Schedule
    6. Boston Scientific Receives FDA Approval of New Clik(TM) Anchor for Precision Plus(TM) Spinal Cord Stimulator System
    7. Boston Scientific to Webcast Analyst Event
    8. Boston Scientific to Present at Barclays Capital 2011 Global Healthcare Conference
    9. Boston Scientific Announces European Approval and Launch of OMEGA™ Platinum Chromium Stent System
    10. Unilife to Present at the 31st Annual Cowen Health Care Conference on Wednesday, March 9, 2011 in Boston
    11. Boston Scientific Strengthens Structural Heart Product Portfolio By Completing Acquisition of Atritech
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/4/2015)... N.J. and LOS ANGELES ... Diagnostics (NYSE: DGX ), the world,s leading ... it has completed the previously announced acquisition of ... As a result of the transaction, ... extensive range of innovative services and network of ...
    (Date:8/4/2015)... 2015  Sutro Biopharma today announced that it ... vice president of alliance and project management. Dr. ... management of Sutro,s collaborative partnerships and the development ... bispecific antibodies and antibody-based therapeutics targeting immuno-oncology pathways. ... years of experience in the biopharmaceutical sector with ...
    (Date:8/4/2015)... 4, 2015  Delcath Systems, Inc. (NASDAQ: DCTH ... on oncology with an emphasis on the treatment of ... summarizing data from studies in Europe ... Hepatic CHEMOSAT ® Delivery System (CHEMOSAT) will be presented ... congress, which will be held in Marseille, ...
    Breaking Medicine Technology:Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California 2Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4
    ... Inc., a neurology-focused specialty pharmaceutical company, announced today that ... of CAMBIA™ (diclofenac potassium for oral solution) will be ... Neurology Conference (CONy) in Barcelona, Spain. The ... entitled, "Rapid and Sustained Improvement in Migraine Symptoms with ...
    ... joint guideline by the American Society of Hematology (ASH) ... physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), ... to produce more red blood cells, to treat cancer ... ESAs are associated with shorter survival and increased risk ...
    Cached Medicine Technology:New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 2New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 3New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 4New Guideline from ASH and ASCO Recommends Caution Regarding ESA Use in Cancer Patients 2New Guideline from ASH and ASCO Recommends Caution Regarding ESA Use in Cancer Patients 3
    (Date:8/4/2015)... (PRWEB) , ... August 05, 2015 , ... The ... Pain and Obesity ”. , As corresponding author Professor Akiko Okifuji says “Both obesity ... often, although it is not to say that one causes the other. Rather, there ...
    (Date:8/4/2015)... ... 2015 , ... Exsurco Medical, Inc. is proud ... as an Affiliate Member. Exsurco Medical finds this an exciting opportunity to ... lives by promoting the safety, quality and availability of donated tissue for transplantation, ...
    (Date:8/4/2015)... ... 2015 , ... The United Nations Foundation today announced a ... for a select group of U.S.-based journalists during the week of November 9, ... International Conference on Family Planning in Bali. , In close coordination with ...
    (Date:8/4/2015)... , ... August 04, 2015 , ... ... formula. Healthy Origins® Cognizin® is a trademark for Citicoline, a nutrient that ... a capsule for those applications which have more of a semi-solid composition. ...
    (Date:8/4/2015)... ... 2015 , ... Bayco Products, Inc. announces a new industrial-grade LED Dual-LightTM headlamp ... hats that have a flip-up face shield. The sleek contours of the new ... to remove their headlamp when raising or lowering their face shield or visor. The ...
    Breaking Medicine News(10 mins):Health News:The Association between Chronic Pain and Obesity published by Dove Medical Press 2Health News:Exsurco Medical Joins AATB as Affiliate Member 2Health News:UN Foundation Announces Press Fellowship to Indonesia with Focus on Women’s Health and Rights 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3
    ... in Wonderland was well advised to stay asleep especially as ... in the tea-time conversation. Dormice in Europe spend about eight ... extended period, with almost all of them surviving the winter. ... Austria, the Czech Republic, England, Germany and Italy. Karin Lebl ...
    ... close attention to how the United Kingdom carries out plans ... beyond clinical and cost effectiveness, according to researchers at the ... to appear in the April 7 issue of the ... discuss a new, "value-based pricing" policy proposed by the British ...
    ... -- Having a good laugh on April Fool,s Day or ... benefits your blood vessels, an expert says. "Laughter increases ... stress is especially beneficial for persons who have hypertension [high ... Vascular Surgery news release. April is National Stress Awareness ...
    ... a unique system to perform in vivo RNAi ... that regulate hepatocyte proliferation during chronic liver damage.1 ... stable knockdown of the candidate gene by different ... mouse hepatocytes and also increase the regenerative capacity ...
    ... 1 issue of the journal SLEEP demonstrates that an ... sleep disturbances, as well as providing positive, indirect benefits ... that the Internet can give parents widespread access to ... children. Results show that there were significant improvements ...
    ... Researchers have found that it may not be necessary to ... analyzing non-tumor tissue may be an effective option, according to ... of the American Association for Cancer Research. "A ... detect the presence of tumor," said lead researcher Dan Mercola, ...
    Cached Medicine News:Health News:Sleeping through danger: the dormouse approach to survival 2Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 2Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 3Health News:Internet program reduces infant and toddler sleep problems, helps moms sleep better too 2Health News:Internet program reduces infant and toddler sleep problems, helps moms sleep better too 3Health News:New tool allows for an alternate method of prostate cancer diagnosis 2
    For the quantitative in vitro determination of creatinine in serum, plasma or urine....
    For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
    For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum...
    For the quantitative in vitro determination of IgE in Human Serum or Plasma....
    Medicine Products: